Magali Devriese

Magali Devriese

Auto-generated profile, based on publicly available information

Magali Devriese

Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint Louis Paris France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in HLA
Verified
Journal Article
Closed access
PDF file
MDMagali Devriese
Magali Devriese
SSSephora Da Silva
Sephora Da Silva
MMMelchior Le Mene
Melchior Le Mene
JRJulien Rouquie
Julien Rouquie
VAVincent Allain
Vincent Allain
JTJean‐Luc Taupin
Jean‐Luc Taupin

12 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
ARAntoine Roux
Antoine Roux
VBVincent Bunel
Vincent Bunel
NBNatalia Belousova
Natalia Belousova
JMJonathan Messika
Jonathan Messika
STSébastien Tanaka
Sébastien Tanaka
FPFrancois Parquin
Francois Parquin
Lung transplant candidates who are highly sensitized against human leucocyte antigen present an ongoing challenge with regards to finding immunologically acceptable donors. Desensitization strategies aimed at reducing preformed donor-specific antibodies have a number of limitations. Imlifidase, an IgG-degrading enzyme derived from Streptococcus pyogenes, is a novel agent that has been used to convert positive crossmatches to negative in kidney transplant candidates, allowing transplantation to occur. We present the first case of imlifidase use for antibody depletion in a highly sensitized lung transplant candidate who went on to undergo a successful bilateral lung transplant.

19 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NSN. Remi Shih
N. Remi Shih
TNThoa Nong
Thoa Nong
CMCathi Murphey
Cathi Murphey
MLMayra Lopez-Cepero
Mayra Lopez-Cepero
PNPeter W. Nickerson
Peter W. Nickerson
JLJar-How Lee
Jar-How Lee
Antibodies reactive to human leukocyte antigens (HLA) represent a barrier for patients awaiting transplantation. Based on reactivity patterns in single-antigen bead (SAB) assays, various epitope matching algorithms have been proposed to improve transplant outcomes. However, some antibody reactivities cannot be explained by amino acid motifs, leading to uncertainty about their clinical relevance. Antibodies against the HLA class II molecule, DQβ0603:DQα0103, present in some candidates, represent one such example. Here, we show that peptides derived from amino acids 119-148 of the HLA class I heavy chain are bound to DQβ0603:DQα0103 proteins and contribute to antibody reactivity through an HLA-DM-dependent process. Moreover, antibody reactivity is impacted by the specific amino acid sequence presented. In summary, we demonstrate that polymorphic HLA class I peptides, bound to HLA class II proteins, can directly or indirectly be part of the antibody binding epitope. Our findings have potential important implications for the field of transplant immunology and for our understanding of adaptive immunity.

22 March 2024 in HLA
Verified
Journal Article
Closed access
MDMagali Devriese
Magali Devriese
JRJulien Rouquie
Julien Rouquie
SSSephora Da Silva
Sephora Da Silva
NBNadine Benassaya
Nadine Benassaya
LMLucie Maillard
Lucie Maillard
JTJean‐Luc Taupin
Jean‐Luc Taupin

4 June 2019 in Vascular Medicine
Verified
Journal Article
Closed access
PDF file
MDMagali Devriese
Magali Devriese
ALAnne Legrand
Anne Legrand
MCMarie-Cécile Courtois
Marie-Cécile Courtois
XJXavier Jeunemaitre
Xavier Jeunemaitre
JAJuliette Albuisson
Juliette Albuisson
Pseudoxanthoma elasticum (PXE) is a rare disorder characterized by skin, eye, and cardiovascular lesions due to ectopic mineralization and fragmentation of elastic fibers of connective tissues. We present an atypical case of PXE with diffuse vascular calcification and negligible skin and eye lesions. The patient was a 37-year-old man suffering from severe bilateral arterial calcifications in superficial femoral and posterior tibial arteries. Eye fundoscopy and skin examination were first considered normal. This phenotype suggested first the diagnosis of Arterial Calcification due to Deficiency of CD73 (ACDC) characterized by mutations in NT5E gene. However, we found two variants in ABCC6 gene, and no variant in NT5E. Skin reexamination revealed few lateral skin papules confined to the scalp. Phenotypic overlap was described in vascular calcification disorders, between GACI and PXE phenotypes, and we discuss here expansion of this overlap, including ACDC phenotype. Identification of these expanding and overlapping phenotypes was enabled by genetic screening of the corresponding genes, in a systematic approach. We propose to create a calcification next generation sequencing (NGS) panel with NT5E, GGCX, ENPP1, and ABCC6 genes to improve the molecular diagnosis of vascular calcification.

22 April 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
MDMagali Devriese
Magali Devriese
FLFrançois A Lemonnier
François A Lemonnier
JLJulien LION
Julien LION
CSCaroline Sayegh
Caroline Sayegh
EFEmma Fleury
Emma Fleury
JTJean-Luc Taupin
Jean-Luc Taupin
In transplantation, anti-HLA Abs, especially targeting the DQ locus, are well-known to lead to rejection. These Abs identified by Luminex single Ag assays recognize polymorphic amino acids on HLA, named eplets. The HLA Eplet Registry included 83 DQ eplets, mainly deduced from amino acid sequence alignments, among which 66 have not been experimentally verified. Because eplet mismatch load may improve organ allocation and transplant outcomes, it is imperative to confirm the genuine reactivity of eplets to validate this approach. Our study aimed to confirm 29 nonverified eplets, using adsorption of eplet-positive patients’ sera on human spleen mononuclear cells and on transfected murine cell clones expressing a unique DQα- and DQβ-chain combination. In addition, we compared the positive beads patterns obtained in the two commercially available Luminex single Ag assays. Among the 29 nonverified DQ eplets studied, 24 were confirmed by this strategy, including the 7 DQα eplets 40E, 40ERV, 75I, 76 V, 129H, 129QS, and 130A and the 17 DQβ eplets 3P, 23L, 45G, 56L, 57 V, 66DR, 66ER, 67VG, 70GT, 74EL, 86A, 87F, 125G, 130R, 135D, 167R, and 185I. However, adsorption results did not allow us to conclude for the five eplets 66IT, 75S, 160D, 175E, and 185T.